These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Pijpe J; van Imhoff GW; Spijkervet FK; Roodenburg JL; Wolbink GJ; Mansour K; Vissink A; Kallenberg CG; Bootsma H Arthritis Rheum; 2005 Sep; 52(9):2740-50. PubMed ID: 16142737 [TBL] [Abstract][Full Text] [Related]
4. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC; Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627 [TBL] [Abstract][Full Text] [Related]
5. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Sankar V; Brennan MT; Kok MR; Leakan RA; Smith JA; Manny J; Baum BJ; Pillemer SR Arthritis Rheum; 2004 Jul; 50(7):2240-5. PubMed ID: 15248223 [TBL] [Abstract][Full Text] [Related]
6. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome. Khurshudian AV Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Jan; 95(1):38-44. PubMed ID: 12539025 [TBL] [Abstract][Full Text] [Related]
7. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Dass S; Bowman SJ; Vital EM; Ikeda K; Pease CT; Hamburger J; Richards A; Rauz S; Emery P Ann Rheum Dis; 2008 Nov; 67(11):1541-4. PubMed ID: 18276741 [TBL] [Abstract][Full Text] [Related]
8. Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjögren's syndrome. Pillemer SR; Brennan MT; Sankar V; Leakan RA; Smith JA; Grisius M; Ligier S; Radfar L; Kok MR; Kingman A; Fox PC Arthritis Rheum; 2004 Aug; 51(4):601-4. PubMed ID: 15334433 [TBL] [Abstract][Full Text] [Related]
9. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome. Pijpe J; Meijer JM; Bootsma H; van der Wal JE; Spijkervet FK; Kallenberg CG; Vissink A; Ihrler S Arthritis Rheum; 2009 Nov; 60(11):3251-6. PubMed ID: 19877054 [TBL] [Abstract][Full Text] [Related]
10. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Steinfeld SD; Tant L; Burmester GR; Teoh NK; Wegener WA; Goldenberg DM; Pradier O Arthritis Res Ther; 2006; 8(4):R129. PubMed ID: 16859536 [TBL] [Abstract][Full Text] [Related]
11. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Petrone D; Condemi JJ; Fife R; Gluck O; Cohen S; Dalgin P Arthritis Rheum; 2002 Mar; 46(3):748-54. PubMed ID: 11920411 [TBL] [Abstract][Full Text] [Related]
12. Comparison of lacrimal and salivary gland involvement in Sjögren's syndrome. Vissink A; Kalk WW; Mansour K; Spijkervet FK; Bootsma H; Roodenburg JL; Kallenberg CG; Nieuw Amerongen AV Arch Otolaryngol Head Neck Surg; 2003 Sep; 129(9):966-71. PubMed ID: 12975269 [TBL] [Abstract][Full Text] [Related]
13. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Van Den Bosch F; Kruithof E; Baeten D; Herssens A; de Keyser F; Mielants H; Veys EM Arthritis Rheum; 2002 Mar; 46(3):755-65. PubMed ID: 11920412 [TBL] [Abstract][Full Text] [Related]
14. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Devauchelle-Pensec V; Pennec Y; Morvan J; Pers JO; Daridon C; Jousse-Joulin S; Roudaut A; Jamin C; Renaudineau Y; Roué IQ; Cochener B; Youinou P; Saraux A Arthritis Rheum; 2007 Mar; 57(2):310-7. PubMed ID: 17330280 [TBL] [Abstract][Full Text] [Related]
15. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Pers JO; Devauchelle V; Daridon C; Bendaoud B; Le Berre R; Bordron A; Hutin P; Renaudineau Y; Dueymes M; Loisel S; Berthou C; Saraux A; Youinou P Arthritis Rheum; 2007 May; 56(5):1464-77. PubMed ID: 17469105 [TBL] [Abstract][Full Text] [Related]
16. Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. Fox RI; Dixon R; Guarrasi V; Krubel S Lupus; 1996 Jun; 5 Suppl 1():S31-6. PubMed ID: 8803908 [TBL] [Abstract][Full Text] [Related]